ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2021
Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease-related declines.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Objective Criteria for Subtle Cognitive Decline in Aging and Preclinical Alzheimer Disease: A Systematic Review.Neurology · 2025Pooled it
- Association Between Cognitively Stimulating Activities and Cognitive Function in Older Adults Living in Residential Care Homes.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2026Article
- Plasma extracellular vesicles and phosphorylated tau 181 as early biomarkers of cognitive impairment in Alzheimer's dementia.Alzheimer's research & therapy · 2026Article
- AD-related plasma biomarkers in centenarians: links to cognition and neuropathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Longitudinal Associations of Multimodal Core 1 Alzheimer Disease Biomarkers With Cognition in Aging and Preclinical Alzheimer Disease.Neurology · 2025Observational
- Voxel-wise insights into early Alzheimer's disease pathology progression: the association with APOE and memory decline.GeroScience · 2025Article
- Association of objective subtle cognitive difficulties with amyloid-β and tau deposition compared to subjective cognitive decline.European journal of nuclear medicine and molecular imaging · 2025Article
- Growth-associated protein 43 is associated with faster functional decline among amyloid-positive individuals with objectively defined subtle cognitive decline and mild cognitive impairment.Neuropsychology · 2025Article
- Associations of Post-Traumatic Stress Disorder and Objective Subtle Cognitive Difficulties in Cognitively Unimpaired Older Veterans.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2024Article
- Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Plasma biomarkers for Alzheimer's and related dementias: A review and outlook for clinical neuropsychology.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2024Review
- Blood Biomarkers of Alzheimer's Disease and Cognition: A Literature Review.Biomolecules · 2024Review
- Longitudinal assessment of plasma biomarkers for early detection of cognitive changes in subjective cognitive decline.Frontiers in aging neuroscience · 2024Article
- Primacy and recency effects in verbal memory are differentially associated with post-mortem frontal cortex p-tau 217 and 202 levels in a mixed sample of community-dwelling older adults.Journal of clinical and experimental neuropsychology · 2023Article
- Association of Stages of Objective Memory Impairment With Incident Symptomatic Cognitive Impairment in Cognitively Normal Individuals.Neurology · 2023Article
- Altered functional connectivity pattern of hippocampal subfields in individuals with objectively-defined subtle cognitive decline and its association with cognition and cerebrospinal fluid biomarkers.The European journal of neuroscience · 2022Article
- Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients.CNS neuroscience & therapeutics · 2022Article
- Increased regional white matter hyperintensity volume in objectively-defined subtle cognitive decline and mild cognitive impairment.Neurobiology of aging · 2022Article
- Memory markers in the continuum of the Alzheimer's clinical syndrome.Alzheimer's research & therapy · 2022Article
- Blood-based Aβ42 increases in the earliest pre-pathological stage before decreasing with progressive amyloid pathology in preclinical models and human subjects: opening new avenues for prevention.Acta neuropathologica · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionObjectively-defined subtle cognitive decline (Obj-SCD) and plasma phosphorylated-tau181 (p-tau181) are promising early Alzheimer's disease (AD) markers. However, associations between Obj-SCD and p-tau181, and their combined prognostic potential, are unknown.
methodsBaseline and 4-year longitudinal p-tau181 changes were compared across cognitively unimpaired (CU;
resultsCU and Obj-SCD has lower baseline p-tau181 than MCI and did not differ from one another. Longitudinally, Obj-SCD had the steepest p-tau181 increase. Obj-SCD/p-tau181-positive participants had the fastest rates of amyloid accumulation, cognitive decline, and functional decline.
conclusionsDespite assumptions that cognitive changes invariably follow biomarker changes, early neuropsychological difficulties may emerge before/concurrently with plasma p-tau181 changes. Combining Obj-SCD and p-tau181, two potentially accessible early markers, was associated with the faster declines in AD-related outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.